Organon posts FY 2025 Emgality sales of USD 174 million up 63%

Organon reported FY 2025 worldwide sales of USD 6.2 billion (down 3%), with U.S. sales of USD 1.6 billion (up 2%) and international sales of USD 4.6 billion (down 5%). FY 2025 cost of sales rose to USD 2.9 billion (up 8%), while gross profit was USD 3.3 billion (down 11%). Selling, general and administrative expenses were USD 1.7 billion (down 2%), and research and development expenses were USD 366 million (down 22%). Interest expense was USD 504 million (down 3%). The company recorded USD 301 million of goodwill impairment and USD 95 million of restructuring costs. By product, FY 2025 sales included Nexplanon/Implanon NXT at USD 921 million (down 4%), Atozet at USD 324 million (down 31%), Singulair at USD 252 million (down 30%), Dulera at USD 153 million (down 25%), and Ontruzant at USD 99 million (down 30%). Offsetting growth drivers included Hadlima at USD 228 million (up 60%), Emgality at USD 174 million (up 63%), Vtama at USD 128 million, and Follistim AQ at USD 264 million (up 11%). Corporate updates included the January 2026 divestiture of the Jada System to Laborie for up to USD 465 million (USD 440 million plus up to USD 25 million in earnouts) and the March 2025 acquisition of U.S. regulatory and commercial rights from Biogen for Tofidence, with an upfront payment of USD 51 million and potential tiered annual net sales milestone payments of up to USD 45 million. Organon also said the FDA expanded Nexplanon’s duration of use to five years in a January 2026 label update and added a REMS-related enhancement to provider certification. For FY 2025 cash flow, cash and cash equivalents were USD 574 million at year-end, net cash provided by operating activities was USD 700 million, net cash used in investing activities was USD 390 million, and net cash used in financing activities was USD 561 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-011125), on February 24, 2026, and is solely responsible for the information contained therein.